Jaguar Animal Health (NASDAQ:JAGX) Releases Quarterly Earnings Results, Beats Estimates By $36.45 EPS

Jaguar Animal Health (NASDAQ:JAGX) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($52.15) by $36.45, Zacks reports.

Jaguar Animal Health Stock Down 3.1%

JAGX traded down $0.03 on Wednesday, hitting $0.95. The company had a trading volume of 177,397 shares, compared to its average volume of 106,993. The company has a market cap of $567,600.00, a PE ratio of -0.00 and a beta of -0.06. Jaguar Animal Health has a 12-month low of $0.72 and a 12-month high of $85.40. The business’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $9.51.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on JAGX shares. Wall Street Zen raised Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.